Most Clicked SNMMI SmartBrief Stories

1. Group backs use of PET-CT in lymphoma staging

SNMMI SmartBrief | Aug 27, 2014

The International Conference on Malignant Lymphomas Imaging Working Group has issued guidelines backing the use of PET-CT for staging FDG-avid lymphomas. In cases where imaging is indicated, PET-CT should be used for evaluating patients' responses to therapy, too. The guidelines, which outline areas for additional investigation, appear in the Journal of Clinical Oncology. Medscape (free registration) (08/21)

2. Probe has potential for noninvasive and surgical imaging, data show

SNMMI SmartBrief | Aug 22, 2014

Ohio State University researchers have found that the peptide-based molecule known as HN1 could be used for optical and nuclear imaging, potentially improving detection and removal of cancerous lesions. Labeled with a radiopharmaceutical, HN1 could help detect cancer, while a fluorescent agent could be appended to it, providing real-time data for surgical excisions. (free registration) (08/22)

3. SPECT/CT imaging useful for guiding back pain treatment, study finds

SNMMI SmartBrief | Aug 26, 2014

A study that reviewed data from 29 patients with low back pain revealed that SPECT/CT data changed management in 76% of patients and could rule out the possibility of infection and distinguish joint and discogenic pain. Details of the study will be discussed at the Royal College of Radiologists Annual Scientific Meeting in London. Diagnostic Imaging (08/25)

4. New domestic HQ for GE Healthcare Life Sciences headed to Mass.

SNMMI SmartBrief | Aug 21, 2014

GE Healthcare Life Sciences has announced it will open a new 160,000-square-foot U.S. headquarters in Marlborough, Mass. The facility will house more than 500 employees and will establish at least 220 new jobs, according to officials. The headquarters, expected to open next year, will have laboratories, office space and more. Genetic Engineering & Biotechnology News (08/20)

5. Trial will test breast cancer imaging technologies

SNMMI SmartBrief | Aug 25, 2014

British researchers will test two Lightpoint Medical imaging devices they say could prevent the removal of healthy tissue during breast cancer surgery. The procedure involves injecting a radioactive imaging agent into the patient and then using a device known as LightPath to scan the surface of the tumor after it is removed. Six months into the trial, a fiber optic camera called EnLight will be incorporated to check for residual cancer. (08/21)

6. $1.5M contract awarded to advance Telik's pancreatic cancer tracer

SNMMI SmartBrief | Aug 26, 2014

Telik has received a $1.5 million contract supported by the National Cancer Institute for the development of a pancreatic cancer PET imaging agent. The company's radiolabeled 5B1 antibody targets a carbohydrate antigen that is heavily expressed in gastric and pancreatic cancer cells. The project involves MabVax Therapeutics, recently merged with Telik, and Memorial Sloan Kettering Cancer Center. (08/25)

7. Image Gently: Updated "Go with the Guidelines" poster available

SNMMI SmartBrief | Aug 25, 2014

When we image, radiation dose matters! Children are more sensitive to radiation; what we do now lasts their lifetime. The 2014 Go with the Guidelines poster is now available to post in your facility! Find it on page 1 of your August 2014 issue of The Journal of Nuclear Medicine -- or download it from the Image Gently site. Visit SNMMI's Dose Optimization page for more resources: Blank (08/04)

8. Protein linked to risk of heart attack and stroke, study finds

SNMMI SmartBrief | Aug 25, 2014

The risk for a heart attack is eight times lower among people who inherit a gene variant from both parents that lowers the expression of fatty acid-binding protein 4, according to a study in the journal Atherosclerosis. The study also linked lower expression of the protein with reduced total cholesterol levels. Genetic Engineering & Biotechnology News (08/22)

9. Agent could guide more precise removal of brain tumors

SNMMI SmartBrief | Aug 26, 2014

Scientists have created a nanoparticle contrast agent, consisting of a dye-coated gold core with a crust of silica, that highlights tumor margins during brain surgery. Researchers tested the agent in mice with glioblastoma tumors. Using a handheld Raman scanner, they found clusters of cancer that were not detectable with normal light or a Raman microscope. Details of the study appear in the journal ACS Nano. Chemical & Engineering News (08/25)

10. Nuclear Medicine and Molecular Imaging Week department bundles are available

SNMMI SmartBrief | Aug 21, 2014

Pick up your 2014 Nuclear Medicine and Molecular Imaging Week merchandise and help show off your love for the profession! Products include car magnets, lunch bags, pens, pins, beverage tumblers, USB chargers and more! Blank (06/18)

Sign up for SNMMI SmartBrief

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession. Learn more